Please assess the completion status of the following clinical trial:

Trial Title: Panitumumab in Combination With Irinotecan Chemotherapy as 2nd-line Therapy in Subjects With mCRC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Man or woman \> 18 years of age~* Competent to comprehend, sign, and date an IEC-approved informed consent form~* Histologically or cytologically-confirmed metastatic adenocarcinoma of the colon or rectum.~* Radiographically documented disease progression per modified RECIST criteria either while receiving or ≤ 6 months after the last dose of prior first-line chemotherapy for mCRC~* At least 1 uni-dimensionally measurable lesion of at least 20 mm per modified RECIST criteria.~* If subject has prior history of cancer other than colorectal carcinoma, basal cell carcinoma, or cervical carcinoma in situ, then subject must not have had treatment or active disease within 5 years.~* Prior radiotherapy is acceptable.~* One and only one prior chemotherapy regimen for mCRC consisting of first-line fluoropyrimidine-based chemotherapy.~* ECOG performance status of 0, 1 or 2~* Life expectancy ≥ 3 months~* Hematologic function:ANC \> 1.5 x 109/L, Platelet count \> 100 x 109/L, Hemoglobin \> 10 g/dL~* Renal function: Creatinine \< 1.5 mg/dL~* Hepatic function: AST and ALT \< 3 x ULN (if liver metastases \< 5 x ULN)~* Bilirubin \< 2 x ULN~Exclusion Criteria:~* No more than one prior chemotherapy regimen for mCRC consisting of first-line fluoropyrimidine-based chemotherapy. (Prior adjuvant fluoropyrimidine-based chemotherapy is allowed)~* Prior systemic therapy for the treatment of metastatic colorectal carcinoma with the exception of adjuvant fluoropyrimidine-based chemotherapy given at least 6 months prior to enrolment.~* Systemic chemotherapy, hormonal therapy, immunotherapy or experimental or approved proteins/antibodies (eg, bevacizumab) ≤ 30 days before inclusion~* Unresolved toxicities from prior systemic therapy that, in the opinion of the investigator, does not qualify the patient for inclusion~* Central nervous system/brain metastases~* Significant cardiovascular disease including unstable angina or myocardial infarction within 6 months before initiating study treatment or a history of ventricular arrhythmia~* Prior anti-EGFr antibody therapy (eg, cetuximab) or treatment small molecule EGFr tyrosine kinase inhibitors (eg, erlotinib)~* History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis on baseline chest CT scan~* Treatment for systemic infection within 14 days before initiating study treatment~* Radiotherapy ≤ 14 days prior to inclusion. Patients must have recovered from all radiotherapy-related toxicities~* Active inflammatory bowel disease or other bowel disease causing chronic diarrhoea (defined as \> 4 loose stools per day)~* History of Gilbert's syndrome or dihydropyrimidine deficiency~* History of any medical condition that may increase the risks associated with study participation or may interfere with the interpretation of the study results~* Known positive test for human immunodeficiency virus infection, hepatitis C virus, chronic active hepatitis B infection~* subject allergic to the ingredients of the study medication or to Staphylococcus protein A~* Any co-morbid disease that would increase risk of toxicity~* Any kind of disorder that compromises the ability of the subject to give written informed consent and/or comply with the study procedures~* Any investigational agent within 30 days before enrolment~* Must not have had a major surgical procedure within 28 days of randomization~* Subject who is pregnant or breast feeding~* Woman or man of childbearing potential not consenting to use adequate contraceptive precautions i.e. double barrier contraceptive methods~* Subject unwilling or unable to comply with study requirements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete